In the last trading session, 1.04 million MaxCyte Inc (NASDAQ:MXCT) shares changed hands as the company’s beta touched 0. With the company’s per share price at $4.50 changed hands at $0.35 or 8.43% during last session, the market valuation stood at $466.11M. MXCT’s last price was a discount, traded about -44.44% off its 52-week high of $6.50. The share price had its 52-week low at $2.45, which suggests the last value was 45.56% up since then. When we look at MaxCyte Inc’s average trading volume, we note the 10-day average is 0.89 million shares, with the 3-month average coming to 839.96K.
Analysts gave the MaxCyte Inc (MXCT) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MXCT as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. MaxCyte Inc’s EPS for the current quarter is expected to be -$0.11.
MaxCyte Inc (NASDAQ:MXCT) trade information
Instantly MXCT was in green as seen at the end of in last trading. With action 29.31%, the performance over the past five days has been green. The jump to weekly highs of 4.51 on Monday, 11/20/23 added 8.43% to the stock’s daily price. The company’s shares are showing year-to-date downside of -17.58%, with the 5-day performance at 29.31% in the green. However, in the 30-day time frame, MaxCyte Inc (NASDAQ:MXCT) is 44.23% up. Looking at the short shares, we see there were 3.26 million shares sold at short interest cover period of 2.87 days.
The consensus price target for the stock as assigned by Wall Street analysts is $9.42, meaning bulls need an upside of 52.23% from its current market value. According to analyst projections, MXCT’s forecast low is $7.00 with $11.00 as the target high. To hit the forecast high, the stock’s price needs a -144.44% plunge from its current level, while the stock would need to soar -55.56% for it to hit the projected low.
MaxCyte Inc (MXCT) estimates and forecasts
Data shows that the MaxCyte Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 9.76% over the past 6 months, a -86.96% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for MaxCyte Inc will fall -120.00%. Year-over-year growth is forecast to reach -20.70% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of $9.53 million. 3 analysts are of the opinion that MaxCyte Inc’s revenue for the quarter ending Mar 2024 will be $9.11 million. The company’s revenue for the corresponding quarters a year ago was $12.42 million and $8.58 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -23.30%. The estimates for the next quarter sales put growth at 6.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -2.60%. The 2023 estimates are for MaxCyte Inc earnings to decrease by -82.61%.
MaxCyte Inc is expected to release its next quarterly earnings report on November 08.